FTC seeks additional information on MiMedx's acquisition of Sanara MedTech
Bitget2026/10/16 13:21- Sanara MedTech and MiMedx received requests for additional information from the Federal Trade Commission on October 15, 2026, extending their merger review.
- The waiting period runs until 30 days following substantial compliance, unless voluntarily extended by the parties or ended earlier by the FTC.
- MiMedx would acquire Sanara as a wholly owned subsidiary; completion remains subject to the waiting period’s expiration or termination and other closing conditions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Crypto prices
More
